Literature DB >> 23417197

Monitoring tumor proliferative response to radiotherapy using (18)F-fluorothymidine in human head and neck cancer xenograft in comparison with Ki-67.

Chowdhury Nusrat Fatema1, Songji Zhao, Yan Zhao, Masahiro Murakami, Wenwen Yu, Ken-Ichi Nishijima, Nagara Tamaki, Yoshimasa Kitagawa, Yuji Kuge.   

Abstract

OBJECTIVE: Although radiotherapy is an important treatment strategy for head and neck cancers, it induces tumor repopulation which adversely affects therapeutic outcome. In this regard, fractionated radiotherapy is widely applied to prevent tumor repopulation. Evaluation of tumor proliferative activity using (18)F-fluorothymidine (FLT), a noninvasive marker of tumor proliferation, may be useful for determining the optimal timing of and dose in the repetitive irradiation. Thus, to assess the potentials of FLT, we evaluated the sequential changes in intratumoral proliferative activity in head and neck cancer xenografts (FaDu) using FLT.
METHODS: FaDu tumor xenografts were established in nude mice and assigned to control and two radiation-treated groups (10 and 20 Gy). Tumor volume was measured daily. (3)H-FLT was injected intravenously 2 h before killing. Mice were killed 6, 24, 48 h, and 7 days after the radiation treatment. Intratumoral (3)H-FLT level was visually and quantitatively assessed by autoradiography. Ki-67 immunohistochemistry (IHC) was performed.
RESULTS: In radiation-treated mice, the tumor growth was significantly suppressed compared with the control group, but the tumor volume in these mice gradually increased with time. In the visual assessment, intratumoral (3)H-FLT level diffusely decreased 6 h after the radiation treatment and then gradually increased with time, whereas no apparent changes were observed in Ki-67 IHC. Six hours after the radiation treatment at 10 and 20 Gy, the intratumoral (3)H-FLT level markedly decreased to 45 and 40 % of the control, respectively (P < 0.0001 vs control), and then gradually increased with time. In each radiation-treated group, the (3)H-FLT levels at 48 h and on day 7 were significantly higher than that at 6 h. The intratumoral (3)H-FLT levels in both treated groups were 68 and 60 % at 24 h (P < 0.001), 71 and 77 % at 48 h (P < 0.001), and 83 and 81 % on day 7 (P = NS) compared with the control group.
CONCLUSION: Intratumoral FLT uptake level markedly decreased at 6 h and then gradually increased with time. Sequential evaluation of intratumoral proliferative activity using FLT can be beneficial for determining the optimal timing of and dose in repetitive irradiation of head and neck cancer.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23417197     DOI: 10.1007/s12149-013-0693-9

Source DB:  PubMed          Journal:  Ann Nucl Med        ISSN: 0914-7187            Impact factor:   2.668


  11 in total

1.  Immunohistochemical quantification of the vitamin B12 transport protein (TCII), cell surface receptor (TCII-R) and Ki-67 in human tumor xenografts.

Authors:  Annette M Sysel; Victor E Valli; Ray B Nagle; Joseph A Bauer
Journal:  Anticancer Res       Date:  2013-10       Impact factor: 2.480

2.  Spatial Concordance of Tumor Proliferation and Accelerated Repopulation from Pathologic Images to 3'-[18F]Fluoro-3'-Deoxythymidine PET Images: a Basic Study Guided for PET-Based Radiotherapy Dose Painting.

Authors:  Chengming Li; Xiaoli Zhang; Linlin Pang; Yong Huang; Yongsheng Gao; Xindong Sun; Jinming Yu; Xue Meng
Journal:  Mol Imaging Biol       Date:  2019-08       Impact factor: 3.488

3.  Evaluation of arginine deiminase treatment in melanoma xenografts using (18)F-FLT PET.

Authors:  Lars Stelter; Simon Fuchs; Achim A Jungbluth; Gerd Ritter; Valerie A Longo; Pat Zanzonico; Nathanael Raschzok; Igor M Sauer; John S Bomalaski; Steven M Larson
Journal:  Mol Imaging Biol       Date:  2013-12       Impact factor: 3.488

4.  Expression and Significance of COX-2 and Ki-67 in Hepatolithiasis with Bile Duct Carcinoma.

Authors:  Ping Wang; Yu He; Xiaodong Ma; Beiwang Sun; Binyuan Huang; Canhua Zhu; Yanmin Liu
Journal:  Med Sci Monit       Date:  2015-10-01

5.  Imaging Mass Spectrometry Revealed the Accumulation Characteristics of the 2-Nitroimidazole-Based Agent "Pimonidazole" in Hypoxia.

Authors:  Yukiko Masaki; Yoichi Shimizu; Takeshi Yoshioka; Fei Feng; Songji Zhao; Kenichi Higashino; Yoshito Numata; Yuji Kuge
Journal:  PLoS One       Date:  2016-08-31       Impact factor: 3.240

6.  Repopulation of tumor cells during fractionated radiotherapy and detection methods (Review).

Authors:  Jia Yang; Jin-Bo Yue; Jing Liu; Jin-Ming Yu
Journal:  Oncol Lett       Date:  2014-03-21       Impact factor: 2.967

7.  Dual tracer evaluation of dynamic changes in intratumoral hypoxic and proliferative states after radiotherapy of human head and neck cancer xenografts using radiolabeled FMISO and FLT.

Authors:  Chowdhury Nusrat Fatema; Songji Zhao; Yan Zhao; Wenwen Yu; Ken-ichi Nishijima; Koichi Yasuda; Yoshimasa Kitagawa; Nagara Tamaki; Yuji Kuge
Journal:  BMC Cancer       Date:  2014-09-22       Impact factor: 4.430

8.  The Impact of the Overall Radiotherapy Time on Clinical Outcome of Patients with Nasopharyngeal Carcinoma; A Retrospective Study.

Authors:  S D Stoker; R Fles; C Herdini; F J F Rijntjes; M Tjokronagoro; S R Dwidanarti; K Sikorska; C R Leemans; M K Schmidt; A Al-Mamgani; M A Wildeman; S M Haryana; S R Indrasari; I B Tan
Journal:  PLoS One       Date:  2016-03-31       Impact factor: 3.240

9.  The accumulation mechanism of the hypoxia imaging probe "FMISO" by imaging mass spectrometry: possible involvement of low-molecular metabolites.

Authors:  Yukiko Masaki; Yoichi Shimizu; Takeshi Yoshioka; Yukari Tanaka; Ken-Ichi Nishijima; Songji Zhao; Kenichi Higashino; Shingo Sakamoto; Yoshito Numata; Yoshitaka Yamaguchi; Nagara Tamaki; Yuji Kuge
Journal:  Sci Rep       Date:  2015-11-19       Impact factor: 4.379

10.  The Role of Tc-99m DTPA Renal Dynamic Scintigraphy in Retroperitoneal Liposarcoma.

Authors:  Ying Wang; Ming Li; Shundong Dai; Yaming Li
Journal:  Biomed Res Int       Date:  2020-02-22       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.